PT-141 (Bremelanotide) Research Guide 2026

PT-141, also known as bremelanotide, is one of the most distinctive compounds in the modern research peptide market. Unlike PDE5 inhibitors that act on the vascular system, PT-141 works upstream, directly in the central nervous system, through the melanocortin receptor pathway. That mechanistic difference is what makes it interesting to researchers studying sexual response, neurobiology, and CNS-mediated arousal.

This guide is the working 2026 reference: how the melanocortin system actually works, what the published trials show, the dosing patterns documented in research, the side effect profile you actually need to plan for, and a strict sourcing checklist for the US market.

For research and laboratory use only. Not medical advice.

What PT-141 Is

PT-141 is a synthetic cyclic heptapeptide derived from Melanotan II (MT-II). The parent compound, MT-II, was originally developed as a sunless tanning agent and was found to produce unexpected sexual effects in early Arizona trials. Researchers stripped the structure down to isolate the sexual-response activity from the tanning activity, and the result was PT-141, a melanocortin agonist optimized for MC3R and MC4R activity with reduced MC1R (pigmentation) effect.

In 2019, the FDA approved bremelanotide under the brand name Vyleesi for premenopausal hypoactive sexual desire disorder (HSDD) in women. That approval is the single deepest source of human safety and efficacy data on the compound.

The Melanocortin Mechanism, Why PT-141 Is Different

Every other widely-known compound for sexual response works downstream, at the level of blood vessels (PDE5 inhibitors like sildenafil, tadalafil) or hormones (testosterone). PT-141 works upstream, in the brain itself.

The melanocortin system is one of the oldest neuropeptide signaling networks in vertebrates. It regulates appetite, pigmentation, inflammation, and, critically for PT-141, central sexual motivation.

Mechanism at a glance:

1. MC4R activation in the hypothalamus. PT-141 binds the melanocortin-4 receptor in the paraventricular nucleus.
2. Downstream dopamine release in the medial preoptic area, which is the brain region most closely linked to sexual motivation in mammalian research.(1)
3. Arousal precedes physical response. Because the effect is centrally mediated, the experience is described in research as a return of desire, not just mechanical capacity.

This is why PT-141 is studied for situations where PDE5 inhibitors fail. PDE5s require pre-existing desire to produce a physical response. PT-141 acts on the desire itself.

What the Clinical Trials Show

The bremelanotide development program ran two large phase 3 trials, RECONNECT, in women with HSDD.(2) The data set is genuinely strong by the standards of sexual-response research, which historically suffers from soft endpoints.

Key trial findings:

• •Statistically significant improvement in desire scores (FSFI-D) versus placebo
• •Significant reduction in distress scores related to low desire
• •On-demand subcutaneous dosing, per the approved FDA label parameters
• •No vascular contraindications of the PDE5 class, PT-141 does not interact with nitrates
• •Smaller male studies have shown response in subjects with PDE5-non-responsive erectile dysfunction, suggesting the central mechanism reaches subjects the vascular drugs cannot

The effect size is modest in statistical terms but consistent, and the mechanism is novel enough that the compound occupies a distinct research category.

Dosing Parameters in the Approved Clinical Protocol

The FDA-approved clinical protocol (Vyleesi) specifies an on-demand subcutaneous dose, with a defined maximum frequency ceiling set on safety and tachyphylaxis grounds, and a reported onset window and duration of effect. See the FDA label and RECONNECT trial publications for the exact approved parameters.

Intranasal PT-141 appeared in earlier development but was found to be less stable and less reliably absorbed, and was abandoned in favor of the subcutaneous route in the approved formulation.

Reconstitution and Concentration

PT-141 ships as a lyophilized powder, typically 10 mg per vial. See our reconstitution concentration reference for the general mg/mL formula used to calculate solution concentration from vial size and diluent volume.

Storage

PT-141 follows standard cyclic peptide stability:

• •Lyophilized: Stable for 24+ months at minus 20 C, 6 to 12 months refrigerated at 2 to 8 C
• •Reconstituted: 4 to 6 weeks at 2 to 8 C with bacteriostatic water (the benzyl alcohol preservative protects against bacterial growth)
• •Do not freeze reconstituted solution. Each freeze-thaw cycle costs purity.
• •Protect from light. Use an amber vial or wrap in foil for long-term storage.

Side Effects, The Real Profile

PT-141 has a distinctive side effect signature because of its melanocortin agonism. The most common documented effects:

• •Nausea: 40 percent of subjects in trials, usually mild to moderate, typically resolving within 2 hours. This is the single most common adverse event, and the FDA label notes that starting-dose and administration conditions affect incidence; see the label for exact parameters.
• •Flushing: 20 to 25 percent, transient
• •Headache: 10 to 15 percent
• •Injection site reactions: under 10 percent
• •Transient blood pressure changes: Small mean increase in systolic BP (~2 to 6 mmHg) for ~12 hours post-dose. This is why the FDA label contraindicates use in subjects with uncontrolled hypertension or known cardiovascular disease.
• •Focal hyperpigmentation: With repeated dosing over months, some subjects develop darkened patches on the face, gums or breasts, a downstream MC1R effect. Reversible after discontinuation but should be monitored.

What PT-141 does not do:

• •It does not cause priapism (a rare but real PDE5 risk)
• •It does not interact with nitrates or PDE5 inhibitors at the vascular level
• •It does not cause vision changes (a rare PDE5 effect)

PT-141 vs Sildenafil/Tadalafil, A Mechanism Comparison

The two classes are mechanistically orthogonal. They are not substitutes, they target different stages of the response.

Who PT-141 Is Studied For

The most-cited research populations:

• •Female subjects with HSDD, the FDA-approved indication
• •Male subjects with erectile dysfunction non-responsive to PDE5 inhibitors, where the failure is upstream
• •Subjects with SSRI-induced sexual dysfunction, a hard-to-treat group where the mechanism is central and PDE5s often fail
• •Subjects with psychogenic rather than vascular dysfunction, where the limiting factor is desire or arousal, not blood flow

PT-141 is not studied as a routine substitute for PDE5 inhibitors in subjects who respond well to them. The compound earns its place when the standard approach hits a ceiling.

Combination Research Notes

PT-141 is rarely studied in combination, since the mechanism is largely self-contained. The few combinations noted in research literature:

• •PT-141 + low-dose tadalafil, studied for separating central and vascular components in mixed-etiology models
• •PT-141 + Kisspeptin-10, early-stage research interest combining melanocortin and HPG-axis signaling
• •PT-141 + Melanotan II, the literature notes shared melanocortin agonism between the two, with additive exposure associated with increased nausea, blood-pressure changes, and pigmentation effects without proportional research benefit

Sourcing, The Checklist for PT-141 in the USA

PT-141 is a short cyclic peptide and is relatively easy to synthesize well, but easy to synthesize poorly. Bad PT-141 in the market typically fails on purity (impurity peaks from incomplete cyclization) or on net peptide content (mass listed is gross lyophilizate, not actual peptide).

Demand for every vial you purchase:

1. Per-lot HPLC at 98 percent or higher
2. Mass spectrometry confirmation, PT-141 molecular weight is 1025.18 Da
3. Net peptide content disclosed, not gross lyophilizate weight
4. Counter-ion percentage disclosed (TFA or acetate)
5. Endotoxin below 5 EU/mg
6. US-warehouse shipping with cold packs for summer transit
7. Vial labeled with lot number that matches the COA

Avoid:

• •Vendors pricing 10 mg PT-141 below ~$28, almost certainly underfilled or impure
• •Vendors who refuse third-party HPLC verification
• •Any vial without a lot number
• •"Pharmaceutical grade" claims for research powder, these are not pharmacy products

Enlife Peptides ships PT-141 from the US warehouse with per-lot COAs, third-party verified purity, honest net-peptide-content labeling, and cold-pack handling. Pricing sits inside the legitimate benchmark range for the compound.

Study Design Considerations in the Trial Literature

The RECONNECT trial program that supported FDA approval of Vyleesi used defined dose-escalation, frequency-cap, and monitoring parameters (blood pressure, nausea, pigmentation) to characterize response over a multi-week study window. This article does not provide dosing, administration, frequency, or titration guidance of any kind; see the FDA label and the published RECONNECT trial protocols for the exact approved parameters.

Frequently Asked Questions

Is PT-141 FDA approved?

Yes, under the brand name Vyleesi, for premenopausal women with hypoactive sexual desire disorder. Research-grade PT-141 powder is not an FDA-approved product and is sold strictly for laboratory and research use, not for human consumption.

How is PT-141 different from Viagra or Cialis?

PT-141 acts in the brain, on melanocortin receptors that regulate sexual motivation. PDE5 inhibitors like Viagra (sildenafil) and Cialis (tadalafil) act in the vasculature, increasing blood flow. PT-141 affects desire; PDE5s affect physical response.

Does PT-141 work in men?

Earlier development trials included male subjects with erectile dysfunction, particularly those who did not respond to PDE5 inhibitors. The data showed meaningful response in that hard-to-treat group, though the FDA approval is for female HSDD. Research continues in male populations.

How long does PT-141 take to work?

Onset is typically 30 to 60 minutes after subcutaneous injection. Effects last 4 to 8 hours.

What are the most common side effects?

Nausea is by far the most common, about 40 percent of subjects in trials. Flushing, headache, and small transient blood pressure increases are also documented. Most side effects are mild and resolve within hours.

Does the literature support combining PT-141 with Melanotan II research?

The literature notes shared melanocortin agonism between the two, with combined exposure associated with increased nausea, blood-pressure response, and pigmentation effects in study populations, without proportional research benefit.

Why buy PT-141 from Enlife Peptides?

US warehouse fulfillment, per-lot HPLC and MS COAs, third-party verification, honest net-peptide-content labeling, cold-pack shipping, and pricing inside the benchmark range. Apply the sourcing checklist in this guide to any vendor, Enlife passes it.

Bottom Line

PT-141 occupies a research category of its own. It is the only widely-available compound that acts centrally on sexual motivation through the melanocortin pathway. The mechanism is novel, the FDA approval gives the safety database real depth, and the dosing protocol is simple and well-characterized. For research subjects where the limiting factor is desire rather than vascular response, including SSRI-induced dysfunction and PDE5 non-responders, PT-141 is the most interesting compound in the modern peptide library.

References

1. Borland JM, Kohut-Jackson AL, Peyla AC, Hall MA, Mermelstein PG, Meisel RL. Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. Neuropharmacology. 2025 Apr 1. PMID: 39793696.
2. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908. PMID: 31599840.

For research and laboratory use only. Not for human consumption.